



TUBEROUS SCLEROSIS COMPLEX AS A MODEL DISORDER IN DEE: ADVANCING PATHOPHYSIOLOGICAL INSIGHTS AND THERAPEUTIC BREAKTHROUGHS IN PEDIATRIC NEUROLOGY AND PSICHIATRY

Rome, November 6th - 7th, 2025
Forma Spazi

**PROVIDER ECM N. 1293
ORGANIZING SECRETARIAT**



Via Volturmo, 2c - 00185 Roma
Ph. +39 06 85355590
E-mail: enzo.cunsolo@ptsroma.it

UNDER THE PATRONAGE OF



Bambino Gesù
OSPEDALE PEDIATRICO



TOR VERGATA
UNIVERSITÀ DEGLI STUDI DI ROMA



ASSOCIAZIONE
SCLEROSI
TUBEROSA



European
Tuberous
Sclerosis
Complex
Association

Making TSC matter



LICE
Lega Italiana
Control l'Epilessia

Sin

SOCIETÀ ITALIANA DI NEUROLOGIA



SINPIA

Società Italiana di Neuropsichiatria
dell'Infanzia e dell'Adolescenza

CONFERENCE VENUE

Forma Spazi
Via Cavour, 181
00184 Roma
www.formaspazi.it

PROVIDER ECM N. 1293 ORGANIZING SECRETARIAT



Meetings & Events

Via Volturmo, 2c
00185 Roma

E-mail: enzo.cunsolo@ptsroma.it

REGISTRATION

Registration (free of charge) is required.
Please scan the QR code to register



RATIONALE

Developmental and epileptic encephalopathies (DEEs) are a group of severe neurodevelopmental disorders characterized by early-onset epilepsy, cognitive and behavioral impairments, and complex treatment challenges. Among these, Tuberous Sclerosis Complex (TSC) stands out as a paradigmatic example. The central nervous system involvement in TSC includes a high prevalence of drug-resistant epilepsy, autism spectrum disorder (ASD), intellectual disability, and a range of neuropsychiatric comorbidities collectively termed TAND (TSC-associated neuropsychiatric disorders).

Over the past decade, TSC has emerged as a powerful model for understanding the pathophysiology of DEEs. This is largely due to the identification of the mTOR signaling pathway as a central molecular mechanism underlying the disease. Importantly, TSC is now one of the very few monogenic DEEs for which disease-specific treatments have been approved. This marks a significant shift from a time when no specific pharmacological options were available. Moreover, TSC has pioneered the concept of preventive treatment in epilepsy, with growing evidence supporting early intervention before the onset of clinical seizures—a strategy increasingly explored in other epileptic syndromes.

In addition, TSC represents a valuable model for syndromic autism, offering unique opportunities to investigate the neurobiological mechanisms of ASD and to explore targeted interventions in well-characterized genetic conditions.

Recent advances in neuroimaging, early EEG biomarkers, and genetic and molecular profiling have also enabled earlier diagnosis and offered promising perspectives for precision medicine approaches.

This two-day international meeting aims to bring together leading experts in pediatric neurology and psychiatry to share the latest insights on TSC as a model disorder in the broader field of DEEs.

By showcasing the most up-to-date clinical and research developments, the meeting intends to foster collaboration across disciplines and translate cutting-edge scientific discoveries into meaningful therapeutic strategies for TSC and related developmental epileptic encephalopathies.

SCIENTIFIC COMMITTEE

Romina Moavero - Chair (Rome, IT)

Pasquale Striano (Genua, IT)

Luigi Mazzone (Rome, IT)

Alessandra Voci (Rome, IT)

Giorgia Sforza (Rome, IT)

Massimiliano Valeriani (Rome, IT)

FACULTY

Sam Amin (Bristol, UK)

Maria Roberta Cilio (Bruxelles, BE)

Raffaella Cusmai (Rome, IT)

Valentina De Giorgis (Pavia, IT)

Carlo Di Bonaventura (Rome, IT)

Giacomo Esposito (Rome, IT)

Carla Fladrowski (Rome, IT)

Stefano Francione (Genoa, IT)

Anna Jansen (Bruxelles, BE)

Sergiusz Józwiak (Warsaw, PL)

Katarzyna Kotulska (Warsaw, PL)

Pavel Kršek (Prague, CZ)

Francesca La Briola (Milan, IT)

Lieven Lagae (Leuven, BE)

Sara Matricardi (Chieti, IT)

Luigi Mazzone (Rome, IT)

Romina Moavero (Rome, IT)

Alessandra Morano (Rome, IT)

Rima Nabbout (Paris, FR)

Francesca Felicia Operto (Catanzaro, IT)

Angelo Russo (Bologna, IT)

Emilio Russo (Catanzaro, IT)

Susanne Schubert-Bast (Frankfurt, DE)

Nicola Specchio (Rome, IT)

Pasquale Striano (Genoa, IT)

Irene Toldo (Padua, IT)

Federico Vigevaro (Rome, IT)

Aglia Vignoli (Milan, IT)

Alessandra Voci (Rome, IT)

ECM

ID EVENTO N. 1293 - 461151 - Tipologia Formativa: RESIDENZIALE - RES.

All'evento sono stati assegnati n. 9 crediti ECM (9 ore formative).

L'evento è stato accreditato presso la Commissione Nazionale ECM ed è rivolto a:

Medici Specialisti in:

- **Neurofisiopatologia**
 - **Neurologia**
 - **Neurochirurgia**
 - **Neuropsichiatria infantile**
 - **Pediatria e Pediatri di libera scelta**
 - **Psichiatria**
-
- **Tecnici di Neurofisiopatologia**
 - **Dietisti**
 - **Terapisti della neuro e psicomotricità dell'età evolutiva**
 - **Logopedisti**
 - **Psicoterapeuti e Psicologi**

Massimo 100 partecipanti

Al fine dell'attribuzione dei crediti formativi, i partecipanti dovranno garantire il 90% della propria presenza nonché compilare la scheda di valutazione e il questionario per la verifica dell'apprendimento.

Il percorso formativo dovrà essere completato entro 72 ore dal termine dell'evento (10 Novembre 2025). Completato il percorso e superato il test di apprendimento, i partecipanti potranno scaricare il certificato relativo al conseguimento dei crediti.

I partecipanti dovranno accedere alla user area con le stesse credenziali (user e password) utilizzate per effettuare l'iscrizione (il link di accesso alla user area sarà inviato a mezzo e-mail).

OBIETTIVO FORMATIVO

Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura

TIPOLOGIA DELL'EVENTO

Congresso/Simposio/Conferenza/Seminario

PROGRAM - NOVEMBER 6th

13:15 - 15:25

SESSION 1

Chairs: *C. Di Bonaventura - S. Jozwiak*

13:15 - 13:30

Welcome and introduction
R. Moavero

13:30 - 13:55

Neonatal EEG monitoring in TSC: catching the very first seizures
M.R. Cilio

13:55 - 14:20

The role of preventive treatment in the management of TSC
K. Kotulska

14:20 - 14:45

The challenge of transition in TSC and other rare epilepsies
R. Nabbout

14:45 - 15:05

Biomarkers of disease severity in TSC
A. Morano

15:05 - 15:25

Discussion

15:25 - 15:45

Coffee Break

15:45 - 17:30

SESSION 2

Chairs: *F. Vigevano - A. Vignoli*

15:45 - 16:10

The development of new targeted therapies for TSC
E. Russo

16:10 - 16:30

Cannabidiol in TSC related epilepsy
I. Toldo

16:30 - 16:50

Everolimus in TSC related epilepsy
S. Jozwiak

16:50 - 17:10

Is there room for alternative pharmacological treatments for LGS and other DEE in TSC?
Susanne Schubert-Bast

17:10 - 17:30

Discussion

17:30 - 19:10

SESSION 3

Chairs: *G. Esposito - F. La Briola*

17:30 - 17:50

The role of epilepsy surgery in TSC related epilepsy
P. Kršek

17:50 - 18:10

Epilepsy surgery in “non focal” epilepsy
S. Francione

18:10 - 18:50

Other non-pharmacological treatments for refractory epilepsy in TSC

- Ketogenic diet
V. De Giorgis

- VNS
A. Russo

18:50 - 19:10

Discussion and end of the first day

PROGRAM - NOVEMBER 7th

09:00 - 11:00

SESSION 4

Chairs: *L. Mazzone - S. Matricardi*

09:00 - 09:25

Early developmental evaluations as a marker of neurodevelopmental disorders

R. Moavero

09:25 - 09:50

Early EEG findings as a biomarker of future neurodevelopment in TSC

L. Lagae

09:50 - 10:15

Modulation of Gut-brain axis as a potential therapeutic target in epilepsy and neurodevelopmental disorders

P. Striano

10:15 - 10:40

Targeted therapies in ASD and neuroinflammation in neurodevelopmental disorders

L. Mazzone

10:40 - 11:00

Discussion

11:00 - 11:15

Coffee Break

11:15 - 13:00

SESSION 5

Chairs: *R. Cusmai - F.F. Operto*

11:15 - 11:30

TSC Association in Italy, Europe and beyond: fostering a network for progress in care

C. Fladrowski - F. La Briola

11:30 - 11:55

Quality of life in TSC

S. Amin

11:55 - 12:20

The development of questionnaires to explore patient related outcome measures in TSC

A. Jansen

12:20 - 12:40


Sleep in TSC

A. Voci

12:40 - 13:00

Discussion and closing remarks

NOTES



A background network diagram with light blue nodes and lines, and horizontal blue lines for writing.

NOTES

NOTES

NOTES

NOTES

CON IL CONTRIBUTO NON CONDIZIONANTE DI



Inspired by **patients.**
Driven by **science.**